Free clinical trials for acute myeloid leukemia near me
5, 6, 7 This is particularly important in patients with leukemia in whom tissue infiltration or disease burden may result in organ dysfunction or poor performance that could be reversible with appropriate therapy. 4 Of importance, patients with such characteristics and poor expected outcomes represent the population that could benefit the most from investigational approaches considering their otherwise dismal prognosis. In addition, such stringent criteria not only may limit the access of ‘unfit’ patients to potentially beneficial therapies, but also limit our ability to extrapolate the safety and efficacy outcomes of new drugs being tested in conventional clinical trials to this subset of patients with unfavorable clinical features. Although some of them are based on clinical reasoning it seems that these criteria are in place more to protect the drug or intervention being studied than the patient itself. How these criteria protect patients is unclear. Most clinical studies in oncology exclude patients with comorbidities, active or recent malignancies, organ dysfunction or poor performance status.
Free clinical trials for acute myeloid leukemia near me trial#
3 Although enrollment rates may differ regionally, there are a number of reasons for such low rate of participation, with clinical trial eligibility criteria likely representing one of them. 2 Despite this need, only 3–5% of patients with cancer treated in the United States currently enroll in clinical trials. This is particularly important for patients for whom there is no optimal standard of care. 1 Importantly, for the patient and the physician, there is an expectation that the investigational therapy will have a beneficial clinical effect. New drugs are first studied in the context of clinical trials not only to test specific clinical hypothesis, but also to protect patients from unanticipated side effects of such therapy. Participation in clinical trials is fundamental for the development of new therapeutic interventions. Relaxation of standard exclusion criteria may increase the pool of patients likely to benefit from therapy. Our results suggest this subset of patients can be safely treated within clinical trials and derive clinical benefit. Main AEs included grades 1 and 2 gastrointestinal toxicities. Median event-free survival was 4.5 months (3.5–5.6). Median overall survival was 7.6 months (4.5–10.7). In view of these results, we expanded the study and treated 79 additional patients: 27 with azacitidine (AZA) and 52 with azacitidine and vorinostat (AZA+V).
Main adverse events (AEs) were grades 1 and 2 gastrointestinal toxicities. Median follow-up was 7.4 months (0.3–29).
Thirty patients (16 with MDS, 14 with AML) were enrolled. Treatment consisted on a combination of azacitidine and vorinostat.
Study included stopping rules for survival and response. To study whether patients with these characteristics can be treated within a clinical trial, we conducted a study for patients with acute myeloid leukemia (AML) or myelodysplastic syndromes (MDS) with poor performance, organ dysfunction or comorbidities. Most clinical trials exclude patients with poor performance or comorbidities.